#Israel #Inspira Technologies #Private Placement #Ra'anana #Respiratory Technology

Inspira Technologies Secures $3.2 Million in Private Placement

Inspira Technologies Oxy B.H.N. Ltd., known for its pioneering work in life-support technologies, has announced an important funding milestone with the pricing of a private placement that will raise approximately $3.2 million. This strategic move signifies robust interest from both new and existing investors in the company's groundbreaking respiratory support technology.

The offering includes the issuance and sale of 4,608,715 ordinary shares and corresponding ordinary warrants, each at a purchase price of $0.70. The terms of the ordinary warrants allow for an exercise at $1.10 per share for a period of eighteen months. This funding is aimed at bolstering the company's operational capacities and advancing its innovative solutions in respiratory care.

Inspira's technology is designed to address a crucial need in modern healthcare, particularly in the mechanical ventilation market, which is estimated to be worth $19 billion. With about 20 million patients suffering from acute respiratory failure in intensive care units each year, Inspira’s products offer life-saving alternatives to traditional mechanical ventilators. The INSPIRA™ ART (Augmented Respiration Technology) is a notable innovation that enhances oxygen saturation levels in patients without the need for invasive ventilation, allowing them to remain awake during treatment.

In addition to the direct health benefits, the INSPIRA ART integrates advanced technology through the HYLA™ blood sensor. This system provides real-time blood monitoring to alert healthcare professionals of significant changes in a patient's condition, assisting doctors in making timely and informed decisions without requiring regular blood draws.

The company already holds FDA clearance for its INSPIRA™ ART100 system, which is approved for use in cardiopulmonary bypass procedures, and has received AMAR certification in Israel for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass functionalities.

As the exclusive placement agent for this offering, Dawson James Securities is playing a crucial role in facilitating the transaction. The company has indicated that the closing of this private placement is expected to take place around December 30, 2024, contingent on the fulfillment of standard closing conditions.

It's essential to note that the securities involved in the offering are offered under a legal exemption from registration requirements, which limits their sale to specific categories of investors and necessitates compliance with U.S. securities laws.

Inspira Technologies continues to innovate not only through its INSPIRA™ ART but also with additional products in development, such as the INSPIRA™ ART500 and the VORTX oxygen delivery system. While these technologies haven’t yet reached the clinical testing phase, they signify a committed trajectory towards enhancing patient care in critical respiratory scenarios.

For those looking to learn more about Inspira Technologies and its suite of capabilities, further information can be found on the company's official website (https://inspira-technologies.com).

In light of these developments, investors and healthcare stakeholders are keenly watching Inspira Technologies as it navigates this promising landscape of respiratory support, aiming to reshape standards of care for critically ill patients worldwide.

Inspira Technologies’ commitment to advancing human health and optimizing life-support mechanisms sets a precedent for future medical innovations, embodying the driving spirit of technological advancement in healthcare.